2023-508558-25-01招募中2 期
Tolerogenic dendritic cell therapy in type 1 diabetes; a phase 1b safety and immunological effecitivity study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
JJ Zwaginga
Scientific
Academisch Ziekenhuis Leiden
研究点 (2)
Loading locations...
相似试验
招募中
不适用
Beta cell regeneration therapy for type 1 diabetes by GLP-1 receptor agonist and insulitype 1 diabetesJPRN-UMIN000006088Department of Metabolic Medicine, Graduate School of Medicine, Osaka University24
终止
2 期
Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 DiabetesDiabetes Mellitus Type 1Autoimmune DiabetesNCT00837759National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)7
招募中
不适用
Immuun interventie met tolerogene dendritische cellen (DC) in type 1 diabetes. Eerste klinische veiligheidsstudie genaamd D-senseDiabetes Mellitus, Type 1ImmunotherapyDendritic cellsSafetyType 1 diabetesImmunotherapieDendritische cellenVeiligheidNL-OMON21892eiden Universitu Medical Center9
招募中
不适用
Immune intervention with tolerogenic dendritic cells in type 1 diabetes. A phase 1 safety study called D-sensediabetestype 1 diabetes10018424NL-OMON50354eids Universitair Medisch Centrum9
招募中
1 期
Anti-viral action against Type 1 diabetes autoimmunityGPPAD-05-AVAnT1ARisk for Type 1 DiabetesMedDRA version: 20.0Level: HLTClassification code: 10012602Term: Diabetes mellitus (incl subtypes) Class: 10027433CTIS2023-507348-35-00Klinikum rechts der Isar der TU Muenchen AöR2,252